hBD-1 vs Mazdutide
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
| Property | hBD-1 | Mazdutide |
|---|---|---|
| Category | Dental & Oral | Weight Management |
| Full Name | Human beta-defensin 1 | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | 4490 Da | ~5,000 Da |
| Half-Life | minutes to hours | 5-7 days |
| Amino Acids | 36 | 37 |
| Typical Dose | 1-10 µg/mL in experimental studies | 1-6 mg weekly in obesity trials |
| Route | Topical/Intraoral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 28 |
| Research Status | Pre-clinical | Clinical |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.